Skip to main
SLDB
SLDB logo

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 52%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences Inc is focused on developing innovative treatments for Duchenne muscular dystrophy (DMD) and has projected significant revenue growth with SGT-003, anticipated to reach risk-adjusted revenues of $1 billion by 2033, up from $90 million in 2028. Early clinical data suggest promising cardiac benefits from SGT-003, with an 8% increase in mean left ventricular ejection fraction observed in patients, indicating potential expansion into the total addressable DMD market. Additionally, improvements in critical biomarkers related to muscle integrity support the company's progress in its gene therapy initiatives, reinforcing a positive outlook for its future clinical developments.

Bears say

Solid Biosciences Inc faces a concerning outlook due to significant risks associated with its lead product, SGT-003, which is primarily aimed at treating Duchenne muscular dystrophy. The company's financial projections hinge on achieving regulatory approval for SGT-003; however, any failure or delays in this process could necessitate downward revisions of its risk-adjusted projections, adversely impacting share price. Additionally, challenges in developing adequate manufacturing capacity for SGT-003 could further constrain sales and revenue potential, compounding the company's vulnerabilities in a competitive and complex gene therapy market.

Solid Biosciences (SLDB) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 52% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 21 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.